Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Date:8/14/2008

m a preclinical study evaluating PCI-32765, an

orally available, selective inhibitor of Bruton's tyrosine kinase,

or Btk, in collagen induced arthritis, an established animal model

for rheumatoid arthritis (RA). Treatment of animals with advanced

disease, with PCI-32765 reduced inflammation and induced regression

of disease.

* Filed an investigational new drug (IND) application for PCI-27483, a

small molecule inhibitor of Factor VIIa being developed both for the

treatment of thrombotic complications of cancer and as an

anti-cancer agent.

* Plan to complete enrollment and evaluation of a Phase 1 trial in

normal volunteers with our Factor VIIa inhibitor, PCI-27483, in the

fourth quarter of calendar 2008.

* Plan to initiate a Phase 1 trial with our oral Btk inhibitor,

PCI-32765, in patients with recurrent B-cell lymphoma in the fourth

quarter of calendar 2008. This study is designed to evaluate safety

and efficacy using a novel pharmacodynamic biomarker.

* Plans are underway to design and conduct a pivotal Phase 3 trial

with motexafin gadolinium in patients with brain metastases from

non-small cell lung cancer receiving whole brain radiation and

stereotactic radiosurgery. This trial is anticipated to begin in the

first half of calendar 2009.

Conference Call and Webcast Details

The Company will hold a conference call today at 4:30 p.m. EDT to discuss fiscal 2008 year-end financial results and achievements and fiscal 2009 guidance. To participate in the conference call, please dial 800-497-0451 for domestic callers and 706-758-3306 for international callers and reference conference passcode 59146626. To access the live audio broadcast or the subsequent archived recording, log on to

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Pharmacyclics Announces It Received Nasdaq Notification
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/24/2014)... PHILADELPHIA , November 24, 2014 ... Reference Workflow, honored for dynamic leadership skills, business acumen ... scientific, technical and medical information products and services, congratulates ... Manager for Clinical Reference and Workflow, Elsevier Clinical Solutions, ... Women Worth Watching ® Awards issue of ...
(Date:11/22/2014)... Boston, MA (PRWEB) November 21, 2014 ... and key investors will gather on December 3rd ... Boston Biotech Conferences series. GeneticRx will take place ... Harvard Medical School and will discuss the present ... gene therapy, exon skipping, and gene editing—as well ...
(Date:11/22/2014)... 22, 2014 The “Chiral Chromatography ... by Material (Metal, Glass, Plastic), by Application [GC, ... - Forecast to 2018” analyses and studies the ... North America, Europe, Asia, and Rest of the ... 15 figures spread through 135 pages and in-depth ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... DJO Incorporated,(NYSE: DJO ), a global provider of ... reported that on August 9, 2007,the U.S. Federal Trade ... the Hart-Scott-Rodino Antitrust Improvements Act of,1976, as amended, for ... Therapeutics, Inc. ("ReAble"). On July 16, 2007, DJO ...
... Valeant Pharmaceuticals ... ... Biosciences,Inc. (Pink Sheets: ARDC) today announced that it has received the ... (NYSE: VRX ). In December 2006, Ardea Biosciences entered ...
... Shareholder Support for Vermed Sale, SAN DIEGO, Aug. ... innovator and leader of,impedance cardiography (ICG) technology, today announced ... progressing well with over 50%,of the necessary shareholder votes ... the Vermed sale. The ratio of votes,received is running ...
Cached Biology Technology:DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 2DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 3DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 4Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc. 2CardioDynamics Provides 2007 Shareholder Meeting Update 2CardioDynamics Provides 2007 Shareholder Meeting Update 3
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
(Date:11/7/2014)... -- In conjunction with the Glendale and ... of the Verdugos has announced the " GLENDALE ... initiative to keep the Verdugo Regional Crime Lab operational after ... of existence, the Lab has processed more than 400 DNA ... "Because our number one priority is the wellbeing ...
(Date:11/6/2014)... team of Florida State University biologists could lead to ... and survive environmental swings such as droughts or floods. ... the journal The Plant Cell , sheds light ... is organized in a cell and how plants regulate ... and others are turned off. , "If you understand ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2
... Researchers at the Yerkes National Primate Research Center, ... prairie voles, an important step toward unlocking the ... application of this technology will enable scientists to ... help identify the brain mechanisms of social bonding ...
... This release is available in German . ... It contains loads of mitochondria, miniature power stations which among ... a voltage similar to that of a battery, which then provides ... have a short circuit. They go full steam ahead all the ...
... from the United States, the other from Canada, put the satellite ... Ellesmere Island, only 600 miles from the North Pole. Their goal ... in the long, dark days of winter in one of the ... in 2003," said David Mech, a renowned U.S. Geological Survey (USGS) ...
Cached Biology News:Yerkes researchers create first transgenic prairie voles 2Brown fat cells make 'spare tires' shrink 2North Pole wolf emails locations to researchers 2North Pole wolf emails locations to researchers 3
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
... Streptavidin-Horseradish Peroxidase Conjugate, 2 ... reporter enzyme molecules for ... in situ hybridization applications.High ... & Labeling & Detection, ...
...
Biology Products: